Novavax $NVAX Stock Up On Australia Approval of COVID-19 Vaccine

  • Post category:Biotechnology
  • Reading time:8 mins read
Get Email Alerts and Follow Us:
SOCIALICON

NVAX stock rose in morning trade on January 20, 2022, after Australia granted provisional registration for Novavax’s COVID-19 vaccine.

Australia Therapeutic Goods Administration (TGA) Grants Provisional Registration for Novavax COVID-19 Vaccine

On January 19, 2022, Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced that Australia’s Therapeutic Goods Administration (TGA) has granted approval for provisional registration of NVX-CoV2373, Novavax’ COVID-19 vaccine (adjuvanted), for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in individuals 18 years of age and older. The vaccine will be supplied to Australia under the brand name Nuvaxovid™.

“The grant of provisional registration of Nuvaxovid by the TGA reflects Novavax’ increasing momentum around the globe and represents the first-protein based COVID-19 vaccine authorized for use in Australia,” said Stanley C. Erck, President and Chief Executive Officer, Novavax. “While the world continues to grapple with the ever-changing nature of the virus, we look forward to delivering our vaccine to the people of Australia. We would also like to extend our gratitude to the Australian clinical trial participants who contributed so significantly to the development of our vaccine.”

Australia has played a pivotal role in Novavax’ Phase 1 and Phase 2 clinical trials supporting the development of Nuvaxovid. Additionally, a booster trial for Nuvaxovid and a Phase 1/2 trial for a combination seasonal influenza and COVID-19 vaccine are currently underway in Australia. Overall, nearly 1,500 Australians have participated in Novavax COVID-19 and combination vaccine clinical trials.

The approval for provisional registration by the TGA is based on the totality of preclinical, manufacturing and clinical trial data submitted for review. This includes two pivotal Phase 3 clinical trials: PREVENT-19 enrolled approximately 30,000 participants in the U.S. and Mexico, the results of which were published in The New England Journal of Medicine (NEJM); and a trial with almost 15,000 participants in the U.K., the results of which were also published in NEJM. In both trials, NVX-CoV2373 demonstrated high efficacy and a reassuring safety and tolerability profile. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups. The most common adverse reactions observed during clinical studies (frequency category of very common ≥1/10) were headache, nausea or vomiting, myalgia, arthralgia, injection site tenderness/pain, fatigue, and malaise. Novavax will continue to collect and analyze real-world data, including the monitoring of safety and the evaluation of variants, as the vaccine is distributed.

Novavax and the Commonwealth of Australia announced an advance purchase agreement (APA) for 51 million doses of Novavax’ COVID-19 vaccine in January 2021, with the option for an additional 10 million doses (up to 61 million doses total). The approval for provisional registration leverages Novavax’ manufacturing partnership with Serum Institute of India (SII), the world’s largest vaccine manufacturer by volume, which will supply initial doses to Australia. It will later be supplemented with data from additional manufacturing sites in Novavax’ global supply chain.

Novavax received conditional marketing authorization (CMA) for NVX-CoV2373 in the European Union and emergency use listing (EUL) from the World Health Organization (WHO). The Novavax/SII vaccine (brand name, Covovax™) recently received emergency use authorization (EUA) in India, Indonesia and the Philippines, as well as EUL from the WHO. The Novavax/SK bioscience vaccine was granted approval in South Korea by the Ministry of Food and Drug Safety (MFDS). The vaccine is also currently under review by multiple regulatory agencies worldwide. The company submitted its complete chemistry, manufacturing and controls (CMC) data package to the U.S. Food and Drug Administration (FDA) at the end of 2021 and expects to submit a request for EUA for the vaccine in the U.S. after one month in accordance with guidance from the FDA regarding submission of all EUA vaccines.

The brand name Nuvaxovid™ has not yet been authorized for use in the U.S. by the FDA. Novavax’ sponsor in Australia is Biocelect Pty. Ltd.

The Therapeutic Goods Administration (TGA) has granted approval for provisional registration of Nuvaxovid™ COVID-19 Vaccine (adjuvanted) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

Important Safety Information

  1. Nuvaxovid is contraindicated in persons who have a hypersensitivity to the active substance, or to any of the excipients.
  2. Events of anaphylaxis have been reported with administration of COVID-19 vaccines. Appropriate medical treatment and supervision should be available in case of an anaphylactic reaction following the administration of the vaccine. A second dose of the vaccine should not be given to those who have experienced anaphylaxis to the first dose of Nuvaxovid.
  3. Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation, or stress–related reactions may occur in association with vaccination as a psychogenic response to the needle injection. It is important that precautions are in place to avoid injury from fainting.
  4. Vaccination should be postponed in individuals suffering from an acute severe febrile illness or acute infection.
  5. Nuvaxovid should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
  6. The efficacy of Nuvaxovid may be lower in immunosuppressed individuals.
  7. Administration of Nuvaxovid in pregnancy should only be considered when the potential benefits outweigh any potential risks for the mother and foetus.
  8. The effects with Nuvaxovid may temporarily affect the ability to drive or use machines.
  9. Individuals may not be fully protected until 7 days after their second dose. As with all vaccines, vaccination with Nuvaxovid may not protect all vaccine recipients.
  10. The most common adverse reactions observed during clinical studies (frequency category of very common ≥1/10) were headache, nausea or vomiting, myalgia, arthralgia, injection site tenderness/pain, fatigue, and malaise.

NVX-CoV2373 is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Novavax’ patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.

Novavax’ COVID-19 vaccine is packaged as a ready-to-use liquid formulation in a vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses (5 mcg antigen and 50 mcg Matrix-M adjuvant) given intramuscularly 21 days apart. The vaccine is stored at 2°- 8° Celsius, enabling the use of existing vaccine supply and cold chain channels. The current assigned shelf life of the vaccine in Australia is 6 months.

Novavax has established partnerships for the manufacture, commercialization and distribution of NVX-CoV2373 worldwide.

📺 Novavax COVID vaccine approved by TGA. What do we know about it? | ABC News

Novavax COVID vaccine approved by TGA. What do we know about it? | ABC News

📈 NVAX Stock Technical Analysis

Nvax Stock

Both the long and short term trends are negative. It is usually better to avoid going long stocks with negative trends. NVAX is currently making a new 52 week low. This is a very bad signal. The S&P500 Index is trading in the upper part of its 52 week range, so NVAX is lagging the market. Prices have been falling strongly lately, it is better to avoid new long positions here.

There is a resistance zone ranging from 217.22 to 217.22. This zone is formed by a combination of multiple trend lines in multiple time frames.

The technical rating of NVAX is bad and it also does not present a quality setup at the moment. The current Setup Rating on NVAX stock is 2 out of 10. Prices have been extended to the downside lately. For a nice entry it is better to wait for a consolidation. Click here to sign up for email alerts on when NVAX stock consolidates and has a Setup Rating of 8 or higher.

Get Email Alerts and Follow Us:
SOCIALICON